Published in Hepatitis Weekly, April 10th, 2006
Study 1: A study from Spain has chronicled the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus (HBV) infection and lamivudine-resistant HBV.
"HBV recurrence and de novo HBV infection are frequent events in liver transplantation recipients. Treatment with lamivudine is initially efficient in both infections but the incidence of lamivudine-resistant HBV emergence increases over time," wrote R. Barcena and colleagues, Hospital Ramon y Cajal.
"Adefovir appears to be promising in post-liver...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.